A pharmacodynamic/Pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases

Clinical Cancer Research

Volumn 20, Issue 10, 2014, Pages 2793-2804

  Tabernero, Josep ^a   Elez, Maria Elena ^a   Herranz, Maria ^a   Rico, Isabel ^a   Prudkin, Ludmila ^a   Andreu, Jordi ^a   Mateos, Jose ^b   Carreras, Maria Josep ^a   Han, May ^c   Gifford, James ^c   Credi, Marc ^c   Yin, Wei ^c   Agarwal, Shefali ^c   Komarnitsky, Philip ^c   Baselga, Jose ^d  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

^c AVEO ONCOLOGY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FICLATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONSTIPATION; COUGHING; DECREASED APPETITE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INTESTINE OBSTRUCTION; LEUKOPENIA; LIVER METASTASIS; LIVER PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS ISLET CELL CARCINOMA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RESPIRATORY FAILURE; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; EDEMA; IMMUNOLOGY; LIVER DISEASES; LIVER NEOPLASMS; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASMS; PAIN; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; ASTHENIA; COUGH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EDEMA; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PAIN; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84901068637     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1837     Document Type: Article

References (39)

1. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251: 802-4.
2. Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 1993; 121:145-54.
3. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility, and more. Nat Rev Mol Cell Biol 2003;4:915-25.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
5. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2: 289-300.
6. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non- small cell lung cancer. Clin Cancer Res 2008;14:2895-9.
7. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008; 27:85-94.
8. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
9. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9.
10. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, et al. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. OncolRep 2008;19:1477-83.
11. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 2009;106:12903-8.
12. Pour L, Svachova H, Adam Z, Mikulkova Z, Buresova L, Kovarova L, et al. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 2010;57:29-34.
13. Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, et al. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci 2007;98:491-8.
14. Hepatocyte growth factor/scatter factor (HGF/SF), MET and cancer references. 2011. http://www.vai.org/met/.
15. Salgia R. Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol 2009;36:S52-S58.
16. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26.
17. Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, et al. c- Met expression in gastric cancer with liver metastasis. Oncology 2002;63:286-96.
18. Coskun U, Bukan N, Sancak B, Gunel N, Ozenirler S, Unal A, et al. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions. Neoplasma 2004;51:209-13.
19. Eichbaum MH, de Rossi TM, Kaul S, Bruckner T, Schneeweiss A, Sohn C. Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer. Tumour Biol 2007;28:36-44.
20. Hansel DE, Rahman A, House M, Ashfaq R, Berg K, Yeo CJ, et al. Met protooncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res 2004;10: 6152-8.
21. Maemura M, Iino Y, Yokoe T, Horiguchi J, Takei H, Koibuchi Y, et al. Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer. Cancer Lett 1998;126:215-20.
22. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008;265:258-69.
23. Han M, Breault L, Wright K, Moore C, Knuehl C, Lin J, et al. In vivo genetic screens designed to complement loss of HER2 or kRas functions identify c-Met/HGF pathway as potent driver of growth/survival in solid tumor models. AACR Meeting Abstracts 2007:4887.
24. Meetze KA, Connolly K, Boudrow A, Venkataraman S, Medicherla S, Gyuris J, et al. Preclinical efficacy and pharmacodynamics of SCH 900105 (AV-299) an anti-HGF antibody in an intracranial glioblastoma model. Mol Cancer Ther 2009;8:C181.
25. Meetze KA, Boudrow A, Connolly K, Huang R, Rideout W, Gyuris J, et al. Anti-tumor activity of SCH 900105 (AV299), an anti-HGF antibody, in non-small cell lung cancer models. Mol Cancer Ther 2009;8: C173.
26. Patnaik A, Weiss GJ, Papadopoulos R, Tibes R, Tolcher AW, Payumo FC, et al. Phase I study of SCH 900105, an anti-hepatocyte growth factor monoclonal antibody, as a single agent and in combination with erlotinib in patients with advanced solid tumors. J Clin Oncol 2010;28:2525.
27. Mok T, Tan E, Park K, Jac J, Han M, Payumo FC, et al. Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol 2011;29: TPS213.
28. Tan E, Park K, Lim WT, Ahn M, Ng QS, Ahn JS, et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor monoclonal antibody in combination with gefitinib in Asian patients with NSCLC. J Clin Oncol 2011;29:7571.
29. National Cancer Institute (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://www.eortc.be/services/doc/ctc/ctcaev3.pdf.
30. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Doseand schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26:1603-10.
31. Detre S, Saclani JG, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-8.
32. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
33. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-5.
34. Ramanathan RK, Payumo FC, Papadopoulos KP, Weiss GJ, Chambers G, Iyengar T, et al. A phase 1, first in human, study ofSCH900105, an antihepatocyte growth factor (HGF) monoclonal antibody, in subjects with advanced solid tumors. Mol Cancer Ther 2009;8:A100.
35. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010;16:699-710.
36. Jones SF, Cohen RB, Bendell JC, Denlinger CS, Harvey RD, Parasuraman S, et al. Safety, tolerability, and pharmacokinetics of TAK- 701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: first-in-human phase I dose-escalation study. J Clin Oncol 2010; 28:3081.
37. Salgia R, Peterson A, Eppler S, Yu W, Polite B, Geary D, et al. A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor Met, administered IV in patients with locally advanced or metastatic solid tumors [abstract]. In: Proceedings of the 20th European Organisation for Research and Treatment of Cancer-National Cancer Institute- American Association for Cancer Research Symposium; 2008 Oct 21-24; Geneva, Switzerland: AACR; 2008. Abstract nr 411.
38. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:493-507.
39. Penuel E, Li C, Parab V, Burton L, Cowan KJ, Merchant M, Yauch RL, et al. HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors. Mol Cancer Ther 2013;12: 1122-3.